“Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance” (2018) SKIN The Journal of Cutaneous Medicine, 2, p. S57. doi:10.25251/skin.2.supp.57.